Navigation Links
Update on velaglucerase alfa
Date:9/8/2009

physician.

In addition, Shire is working with regulatory authorities towards the approval of velaglucerase alfa and has announced, earlier last week, that based on the positive results from all phase 3 trials, it has submitted the New Drug Application to the U.S. Food & Drug Administration and is expected to submit the EU application by year end.

In order to help physicians plan with their patients, Shire has today sent a letter to physicians in the U.S. This letter is to be posted on http://www.gaucherpatients.com.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materi
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
2. ThromboGenics NV Announces Business Update and Half Year Results 2009
3. Wyeth Provides Regulatory Update on Prevnar 13* in the United States
4. ThermoGenesis Provides Update on Fiscal 2009 Results
5. ADVENTRX to Hold Second Quarter Results and Business Update Conference Call on August 12
6. GeoVax Labs, Inc. Provides Clinical Studies Update
7. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
8. SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS
9. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
10. Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
11. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ntly announced that Dr. Dominique Hebrault will pr...nalytical Technology (PAT) in Green Chemistry and ... (PRWEB) November 20, 2009 -...ology (PAT) in Green Chemistry and Green Engineeri...nology (PAT) case studies will be presented on how...
(Date:11/19/2009)...e/ -- Dr. Mate Hidvegi, inventor of Avemar ferment... issued on November 17 by Biropharma Kft, discredi...lf-serving statements about its U.S. competitor Am... his office in Budapest, Hungary: ,, "The Biro...y to AveULTRA, www.aveultra.com , is misleading...
(Date:11/19/2009)...., Nov. 19 Arlington Medical Resou...ading driver of antibiotic selection in nosocomial...ainst gram-positive and gram-negative pathogens. D...comial pneumonia, surveyed European physicians rev...de appropriate coverage against common pathogens, ...
(Date:11/19/2009)...nthesis Companies Form International Gene Synthesi...n Risk Reduction ,Five Member Companies Represen... , (PRWEB) November 19, 20...esis companies today announced agreement that they... biosecurity in the gene synthesis industry. By s...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
...ate vaccines for avian flu through genet...CKVILLE, Md., Nov. 13 Novavax, Inc.,(Nasdaq: NVA... avian flu,through genetically-engineered virus-li...tion at Cleveland Clinic 6th Annual Medical Innova...initiatives have the potential to,impact millions ...
... Genaera,Corporation (Nasdaq: GENR ) will presen...the Congress Center in Mannheim, Germany. Dr. Henr...ific Officer, will present,a company overview on T...ut Genaera, Genaera Corporation is developing tro...ity currently in phase 1 clinical testing and has ...
...nta Holding,Corporation (NYSE: CVA ), a world lea...rgy-from-Waste and renewable energy facilities, to... purchase two biomass energy,facilities from co-ow...vices, Inc., Pursuant to the amended agreement, C...for approximately $52 million subject to working c...
Other Biology Technology:Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 2Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 3Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 4Genaera to Present at BIO-Europe 2008 2Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine 2Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine 3Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine 4
(Date:11/23/2009)...e in German . , Not just birds, but also a .... Researchers at Princeton University in the U.S. ... Radolfzell, Germany studied the migratory behavio...lled "Vespertilionidae" with the help of mathemati...r short as well as long distances of various kinds...
(Date:11/22/2009)...cientists have inventoried an astonishing abundanc...that have never known sunlight - creatures that so... to 5,000 meters (~3 miles) below the ocean waves....ther vanguard technologies, animals known to thriv... a diverse collection of species ranging from crab...
(Date:11/22/2009)...esearch Centre, a partnership of the University of...r Coastal Health Research Institute, have uncovere...in cells die following a stroke, as well as a poss...he study were recently published online in Nature...ls continue to die even after blood flow has been ...
Breaking Biology News(10 mins):We're off then: The evolution of bat migration 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 3Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 4Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 5Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 6Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 7Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 8Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 9New understanding about mechanism for cell death after stroke leads to possible therapy 21 in 4 nursing home residents carry MRSA 47915 11 in 4 nursing home residents carry MRSA 47915 2New Option for Erasing Wrinkles 47913 1New Option for Erasing Wrinkles 47913 2New Option for Erasing Wrinkles 47913 3New Option for Erasing Wrinkles 47913 4Keys to a Fit Pregnancy and Losing the Baby Weight 47910 1Keys to a Fit Pregnancy and Losing the Baby Weight 47910 2Keys to a Fit Pregnancy and Losing the Baby Weight 47910 3
...s discovered a new ultra-small species of bacteria...hin the ice of a Greenland glacier at a depth of n...ersist in this low-temperature, high-pressure, red...rticularly useful for studying how life, in genera...s on Earth and possibly elsewhere in the solar sys...
...m among scientists has long been that birds acquir...ood health from their environment, but a new Unive...ually born with those bacteria. , Lead author Adr... at the American Society for Microbiology General ...ns for the poultry industry and for food safety. ,...
... commonplace everyday events than meets the eye. T...m a tap, are two such events, both of which involv...cated mathematical techniques to describe, analyse...in common between many such singular events across...actions to the very formation of the universe itse...
Other Biology News:A survivor in Greenland: A novel bacterial species is found trapped in 120,000-year-old ice 2Study finds healthy intestinal bacteria within chicken eggs 2Finding out what the Big Bang and ink jets have in common 2Finding out what the Big Bang and ink jets have in common 3
Direct ELISA Assay Diluent from BioFX Laboratories, Inc.
Direct ELISA Assay Diluent - EDTA from BioFX Laboratories, Inc.
Rabbit Anti-Mouse Junctophilin-4, C-Terminus Monoclonal Antibody, Unconjugated, Clone PADZMD.487 from Invitrogen
Fluorescence Preserving Media from BioFX Laboratories, Inc.
Biology Products: